Erythropoietin therapy and the cardiovascular system

Contributions to Nephrology

Volumn 137, Issue , 2002, Pages 431-435

  Santoro, Antonio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN;

ANEMIA; ARTICLE; CARDIOVASCULAR SYSTEM; DRUG EFFECT; HEART DISEASE; HUMAN; PATHOPHYSIOLOGY; UREMIA; VASCULAR RESISTANCE;

ANEMIA; CARDIOVASCULAR SYSTEM; ERYTHROPOIETIN; HEART DISEASES; HUMANS; UREMIA; VASCULAR RESISTANCE;

EID: 0036052809     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000060247     Document Type: Article

References (15)

1. The USRDS Dialysis Morbidity and Mortality Study: Wave 2 US Renal Data System. Am J Kidney Dis 1997;30(suppl 1):567-586.
2. London M, Fabiani F, Marchais SJ, et al: Uremic cardiomyopathy: An inadequate left ventricular hypertrophy. Kidney Int 1987;31:973-980.
3. Katz AM: The cardiomyopathy of overload: An unnatural growth response in hypertrophied heart. Ann Intern Med 1994;121:363-371.
4. Levin A, Thompson CR, Ethier J, et al: Left-ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kid Dis 1999;34:125-134.
5. Neil WA, Oxendine JM, Moore SC: Acute and chronic cardiovascular adjustments to induce anemia in dogs. Am J Physiol 1969;217:710-714.
6. Roy SB, Bhatia ML, Mathur VS, et al: Hemodynamic effects of chronic severe anemia. Circulation 1963;28:346-356.
7. Foley RN, Parfrey PS, Harnett JD, et al: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-192.
8. Madore F, Lowrie EG, Brugnara C, et al: Anemia in hemodialysis patients: Variable affecting this outcome predictor. JASN 1997;8:1921-1929.
9. Greaves Sc, Gamble GD, Collins JF, et al: Determinant of left ventricular hypertrophy and systolic dysfunction in chronic renal failure. Am J Kid Dis 1994;24:768-778.
10. Mayer G, Thum J, Cada EM, Stumvol HK, Graf H: Working capacity is increased following recombinant human erythropoietin treatment. Kidney Int 1988;34:525-528.
11. Besarab A, Bolton WK, Browne JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoietin. N Engl J Med 1998;339:584-590.
12. Goldberg N, Lundin AP, Delano B, Friedman El, Stein RA: Changes in left ventricular size, wall thickness and function in anemic patients treated with recombinant human Erythropoietin. Am Heart J 1992;124:424-427.
13. Pascual J, Teruel JL, Moya Jl, et al: Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: A prospective study. Clin Nephrol 1991;35:280-287.
14. London GM, Zins B, Pannier B, et al: Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 1989;36:878-882.
15. McMahon LP, Mason K, Skinner SL: Effects of hemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 2000;15:1425-1430.